SKIP TO MAIN CONTENT

SKIP TO SEARCH
Skip to...
Select
DOW JONES, A NEWS CORP COMPANY
About WSJ
DJIA32812.79 points with a0.10%▲ S&P 5003950.38 points with a0.18%▲
Nasdaq13388.92 points with a0.52%▲ U.S. 10 Yr2/32 Yieldwith a1.613%▲ Crude
Oil65.27 points with a0.52%▼ Euro1.1925 points with a0.25%▼
The Wall Street Journal
SubscribeSign In
English Edition
Print EditionVideoPodcastsLatest Headlines
Home
World
U.S.
Politics
Economy
Business
Tech
Markets
Opinion
Life & Arts
Real Estate
WSJ. Magazine
Search

CORONAVIRUS
Resources
LATEST UPDATES
POST-VACCINATION Q&A
HOW TO GET A VACCINE
VACCINE DISTRIBUTION
STATE-BY-STATE VACCINE GUIDE
COVID STORM SERIES
BUSINESS HEALTH CARE HEALTH
Germany, France, Italy Suspend Use of AstraZeneca’s Covid-19 Vaccine
Countries are the latest to temporarily stop giving the vaccine amid a small number
of cases of blood clotting on the continent

A healthcare practitioner in Germany administering the AstraZeneca vaccine on March

3, just days before the country paused the vaccine’s use.
PHOTO: ACTION PRESS/ZUMA PRESS
By Bojan Pancevski and Jenny Strasburg
Updated March 15, 2021 1:55 pm ET
PRINT
TEXT

BERLIN—Germany, France and Italy joined a group of smaller European countries that
have temporarily stopped administering Covid-19 vaccines made by AstraZeneca AZN
0.44% PLC, saying the move was precautionary amid a small number of cases of blood
clotting reported on the continent.

Denmark last week said it had paused AstraZeneca shots for two weeks following
reports of blood clotting, and several other European countries quickly followed
suit, saying they were doing so out of an abundance of caution. Norway, Ireland and
the Netherlands are among countries that have paused vaccinating with AstraZeneca’s
shot.

Health regulators in the U.K. and Europe, along with AstraZeneca and its vaccine
development partners at the University of Oxford, say there is no known connection
between severe clotting and the shot. AstraZeneca has said the number of cases of
blood clotting among the roughly 17 million people in the European Union and U.K.
who have received the shot is lower than for the general population.

Europe’s medicines regulator said last week it was looking into around 30 reported
cases of severe clotting, out of around five million people who have received the
shot in the bloc. Last week, the regulator, the European Medicines Agency, said the
“vaccine’s benefits currently still outweigh risks” and has continued recommending
its use. The agency said most side effects are mild or moderate. Clinical trials
didn’t raise flags about blood clotting as a risk.

THE ASTRAZENECA VACCINE

Denmark and Norway Suspend AstraZeneca Covid-19 Vaccine Over Blood Clot Worries
(March 11)
AstraZeneca Warns Europe of Large Delivery Shortfall, Blaming Export Curbs (March
12)
Doses of AstraZeneca’s Vaccine Pile Up in Europe Amid Government Restrictions
(March 2)
The temporary halt to the AstraZeneca shots is another major setback in a wider
vaccine rollout in Europe hamstrung by supply shortages and other hurdles at the
same time as the continent wrestles with rising Covid-19 cases. Europe’s
vaccination rates are far lower than in the U.S. and the U.K., where Covid-19 cases
have stabilized or are falling.

Delays in giving out the AstraZeneca vaccine threaten to exacerbate vaccination-

drive woes and could put further pressure on governments trying to speed things up.
AstraZeneca has become a particular target of European politicians who have accused
it of not doing enough to provide the continent with more shots.

French President Emmanuel Macron, in announcing his country’s pause, said the EMA
was expected to publish a recommendation regarding the vaccine on Tuesday. The
agency didn’t immediately respond to a request for comment.

The series of pauses across Europe threatens to undermine the AstraZeneca vaccine’s
credibility just three months into its rollout. The U.K. was the first country to
adopt the shot for mass use, at the end of December.

The shot previously faced skepticism over clinical-trial results that suggested it
wasn’t as effective as other vaccines hitting the market. Some of those perceptions
have faded as the U.K. inoculated millions of people with the shot, generating
real-world data that showed it to be strongly effective in preventing severe
disease and death.

The U.K.’s relatively quick vaccination program—with some 11 million AstraZeneca

shots playing a key role—hasn’t raised blood-clotting concerns. The British
medicines regulator has said it maintains its confidence in the vaccine and its
safety.

Last week, reports surfaced of a potential clotting issue, with one death and a
case of severe illness, in Austria. That country suspended one batch of the vaccine
but said it didn’t have evidence of a connection between the health incidents and
the shot and kept using it otherwise.

AstraZeneca has warned it would fall short of projected vaccine deliveries to

Europe in coming months.
PHOTO: SEAN GALLUP/ZUMA PRESS
On Thursday, Denmark, Norway and Iceland halted use of the vaccine altogether.
Danish authorities said they would wait at least two weeks before administering it
again. The EMA, which acts much like the Food and Drug Administration in regulating
medicine across the European Union, has already said serious blood clots weren’t
any more common among vaccinated people than among the general population. It has
said it is investigating the reported cases of multiple thrombosis, or the
formation of blood clots within blood vessels, and similar conditions.

Last week, AstraZeneca warned it would fall short of projected vaccine deliveries
to Europe in coming months, by 100 million doses—almost two-thirds less than what
the continent was expecting based on the company’s earlier pledges.

AstraZeneca Chief Executive Pascal Soriot has repeatedly pushed back against doubts
about the shot’s effectiveness and criticism of its rollout. Last month,
AstraZeneca said it would roughly double global vaccine production to 200 million
doses a month by April.

In Germany, the Paul Ehrlich Institute, which regulates vaccine use, said it became
concerned by an unspecified number of new cases showing thrombosis, blood-platelet
deficiency and bleeding in people soon after vaccination with the AstraZeneca shot.
In a statement on its website Monday, the institute said it recommended temporarily
halting use of the vaccine until further study by the EMA after seeing what it
called a “striking accumulation” of those symptoms.

The regulator recommended that people who “feel increasingly unwell” more than four
days after receiving a vaccination should seek medical attention. It flagged
severe, persistent headaches or “pinpoint bleeding” of the skin as symptoms of
concern.

On Friday, a nonprofit global organization of specialists in blood-clotting

disorders and research, the Chapel Hill, N.C.-based International Society on
Thrombosis and Haemostasis, advised continued use of the AstraZeneca vaccine. The
society said that based on available data, the benefits of vaccination outweigh the
risks “even for patients with a history of blood clots or for those taking blood-
thinning medications.”

Covid-19 itself is known to cause blood clots, a factor researchers say they are
taking into account when considering the benefits versus potential risks of
vaccination.

Related Video
The Science Behind Why New Covid Variants Are Spreading Faster
YOU MAY ALSO LIKE

UP NEXT

The Science Behind Why New Covid Variants Are Spreading Faster
The Science Behind Why New Covid Variants Are Spreading Faster
As highly transmissible coronavirus variants sweep across the world, scientists are
racing to understand why these new versions of the virus are spreading faster, and
what this could mean for vaccine efforts. New research says the key may be the
spike protein, which gives the coronavirus its unmistakable shape. Illustration:
Nick Collingwood/WSJ
Covid-19 Vaccines
Behind America’s Botched Vaccination Rollout
Behind America’s Botched Vaccination Rollout
Why It's So Hard to Get Shots in Arms
Why It's So Hard to Get Shots in Arms
Russia Works to Undermine Trust in Vaccines
Russia Works to Undermine Trust in Vaccines
Scientists Warn Against Single-Shot Dose of Pfizer, Moderna Vaccines
Scientists Warn Against Single-Shot Dose of Pfizer, Moderna Vaccines
Why mRNA Vaccines Are So Hard to Mass Produce
Why mRNA Vaccines Are So Hard to Mass Produce
How Vaccine Passports Might Work
How Vaccine Passports Might Work
You May Soon Be Able to Get Vaccinated at Work
You May Soon Be Able to Get Vaccinated at Work
Guide to the Different Vaccines and How They Work
Guide to the Different Vaccines and How They Work
Write to Bojan Pancevski at bojan.pancevski@wsj.com and Jenny Strasburg at
jenny.strasburg@wsj.com

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved.
87990cbe856818d5eddac44c7b1cdeb8
MOST POPULAR NEWS
What You Can and Can’t Do if You’ve Been Vaccinated: Travel, Risk Factors, What You
Need to Know
What You Can and Can’t Do if You’ve Been Vaccinated: Travel, Risk Factors, What You
Need to Know
Fauci Warns Against Easing Covid-19 Restrictions
Fauci Warns Against Easing Covid-19 Restrictions
Third Stimulus Check: When Are the $1,400 Payments Coming and Who Is Eligible?
Third Stimulus Check: When Are the $1,400 Payments Coming and Who Is Eligible?
Short Sellers Boost Bets Against SPACs
Short Sellers Boost Bets Against SPACs
China Begins Withdrawing Pandemic Stimulus Efforts
China Begins Withdrawing Pandemic Stimulus Efforts
MOST POPULAR OPINION
Andrew Cuomo Becomes Expendable
Opinion: Andrew Cuomo Becomes Expendable
Come Back to Florida for Spring Break
Opinion: Come Back to Florida for Spring Break
Opportunity Beckons in the Mideast
Opinion: Opportunity Beckons in the Mideast
The Biden Border Mess
Opinion: The Biden Border Mess
New York’s Hot Export: People
Opinion: New York’s Hot Export: People
MOST POPULAR VIDEOS
[https://m.wsj.net/video/20210315/splash9/splash9_167x94.jpg]
Israel's Final Covid Vaccination Push: Live Music, Free Drinks
[https://m.wsj.net/video/20210310/031121nfts/031121nfts_167x94.jpg]
NFTs Are Fueling a Boom in Digital Art. Here’s How They Work
[https://m.wsj.net/video/20210315/031521grammyssplash/031521grammyssplash_167x94.jp
g]
Grammys 2021: Beyoncé and Taylor Swift Win Big
[https://m.wsj.net/video/20210312/031221royaljobsv2/031221royaljobsv2_167x94.jpg]
Why Prince Harry and Meghan Were Cut Off Financially From the Palace
[https://m.wsj.net/video/20210309/030921marsroverupdate4/030921marsroverupdate4_167
x94.jpg]
The Search for Life on Mars: What's Next for NASA’s Perseverance Rover
WSJ opens select articles to reader conversation to promote thoughtful dialogue.
See the 'Join the Conversation' area to the right for stories open to conversation.
For more information, please reference our community guidelines. Email feedback and
questions to moderator@wsj.com.
JOIN THE CONVERSATION
When CEOs Really Think We’ll Come Back to WorkChina Becomes First Major Economy to
Start Withdrawing Pandemic Stimulus EffortsElectric-Vehicle Startups Promise
Record-Setting Revenue GrowthIn Size and Risk, Biden’s Opening Gamble Ranks With
Reagan’sShort Sellers Boost Bets Against SPACsDemocrats’ Appetite for Progressive
Politics Gets Fresh Test in OhioU.S. Banks Will Turn Last Year’s Fear Into This
Year’s ProfitsSouth Africa’s Drop in Covid-19 Cases Adds to Questions About Waves
of InfectionsWhite House Weighs How to Pay for Long-Term Economic ProgramColleges
Begin Mapping Out a More Normal Fall—With Caveats
The Wall Street Journal
English Edition
Subscribe NowSign In
BACK TO TOP«
WSJ Membership

WSJ+ Membership Benefits

Subscription Options
Why Subscribe?
Corporate Subscriptions
Professor Journal
Student Journal
WSJ High School Program
WSJ Amenity Program
WSJ Live
Customer Service

Customer Center
Contact Us
Tools & Features

Guides
Topics
My News
RSS Feeds
Video Center
Watchlist
Podcasts
Advertise
Commercial Real Estate Ads
Place a Classified Ad
Sell Your Business
Sell Your Home
Recruitment & Career Ads
Coupons
More

About Us
Commercial Partnerships
Content Partnerships
Corrections
Jobs at WSJ
News Archive
Register for Free
Reprints
Buy Issues
Facebook
Twitter
Instagram
YouTube
Podcasts
Snapchat
Google Play
App Store
Dow Jones ProductsBarron'sBigChartsDow Jones NewswiresFactivaFinancial NewsMansion
GlobalMarketWatchPrivate MarketsRisk & ComplianceWSJ ProWSJ VideoWSJ Wine
Privacy NoticeCookie NoticeCopyright PolicyData PolicySubscriber Agreement & Terms
of UseYour Ad Choices
Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved.